Verona Pharma price target raised to $75 from $60 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $75 from $60 and keeps a Buy rating on the shares following the Q4 report. The commercialization of Verona’s sole marketed product, ensifentrine, “continues apace,” the analyst tells investors in a research note. The firm says the company is on a path to cash flow breakeven.